Using molecules called AbLecs that block an immune checkpoint, researchers showed they could stimulate a strong anti-tumor immune response. The approach, which could work for many types of cancer, was developed by Jessica Stark of MIT and Carolyn Bertozzi of Stanford.

MIT is a renowned institution for education and research, offering insights into science, engineering, and technology. Through publications, research papers, and academic programs, MIT's platform provides insights into  research, innovation, and education in various fields. Students, researchers, and technology enthusiasts can learn about MIT's contributions to science and technology and explore opportunities for academic and professional development.

MIT News

MIT and Stanford researchers developed AbLecs, a new immunotherapy approach that blocks glycan-based immune checkpoints on cancer cells. By combining lectins with tumor-targeting antibodies, AbLecs prevent sialic acids on cancer cells from suppressing immune responses, allowing immune cells to attack tumors. The modular system allows swapping different antibodies and lectins to target various cancer types. Mouse studies showed significantly reduced lung metastases compared to standard antibody treatment alone. A company called Valora Therapeutics is developing the technology for clinical trials within 2-3 years.

A new immunotherapy approach could work for many types of cancer